“…Recently, bevacizumab (Avastin), a synthetic monoclonal antibody against vascular endothelial growth factor (anti-VEGF), was reported to limit scar formation after glaucoma filtration surgery and effectively decreased IOP of patients [4,7,8] . However, multiple subconjunctival injections of 5FU or bevacizumab after surgery are required to maintain a high drug concentration [4,9,10] . This process is usually associated with several undesirable complications such as conjunctival wound leaks, corneal epithelial defects, endophthalmitis, cataracts and other ocular diseases [6] .…”